Active	Status	Sponsor type	Region	Phase	Filter
13 Active 1 Inactive 14 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

11 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Patel, Kalpesh R
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent	Terminated	3	105	US	VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga	Veru Inc.	Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer	05/23	05/23
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)	Recruiting	3	10000	Europe, Canada, US, RoW	Retatrutide, LY3437943, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)	02/29	02/29
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity	Active, not recruiting	3	15374	Europe, Canada, Japan, US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Obesity, Overweight	10/27	10/27
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following	Recruiting	3	364	Canada, US	Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma	01/28	01/30
VERU-100, NCT04843319: To Determine an Effective Dose of for the Treatment of Advanced Prostate Cancer	Terminated	1b/2	24	US	VERU-100	Veru Inc.	Advanced Prostate Adenocarcinoma	01/23	01/23
AEROLITH, NCT04563039: Acoustic Enhancer Research on Laser Lithotripsy	Active, not recruiting	N/A	196	US	Ureteroscopy Laser Lithotripsy (URS-LL) with Acoustic Enhancer, Standard Ureteroscopic Laser Lithotripsy	Applaud Medical, Inc.	Urinary Stones	06/23	08/24
NCT04757116: Post-Market Study to Assess iTind Safety in Comparison to UroLift	Recruiting	N/A	206	Europe, US	iTind, UroLift	Olympus Corporation of the Americas	Benign Prostatic Hyperplasia (BPH)	12/25	12/30
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer	Active, not recruiting	N/A	400	US	Vanquish System	Francis Medical Inc.	Prostate Cancer	04/27	04/29
Schiff, William
ESSENCE, NCT05882318: Effectiveness of eCoin at Sensory and Subsensory Amplitudes	Completed	N/A	47	US	eCoin Peripheral Neurostimulator System	Valencia Technologies Corporation	Urge Incontinence	04/24	05/24
NCT04757116: Post-Market Study to Assess iTind Safety in Comparison to UroLift	Recruiting	N/A	206	Europe, US	iTind, UroLift	Olympus Corporation of the Americas	Benign Prostatic Hyperplasia (BPH)	12/25	12/30
Santeufemia, Kristin
ESSENCE, NCT05882318: Effectiveness of eCoin at Sensory and Subsensory Amplitudes	Completed	N/A	47	US	eCoin Peripheral Neurostimulator System	Valencia Technologies Corporation	Urge Incontinence	04/24	05/24